2023
Incisional infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for suspected gynecologic malignancy: a pilot study
Moon A, Andikyan V, Agarwal R, Stroever S, Misita D, Laibangyang A, Doo D, Chuang L. Incisional infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for suspected gynecologic malignancy: a pilot study. Gynecologic Oncology Reports 2023, 47: 101203. PMID: 37251783, PMCID: PMC10220396, DOI: 10.1016/j.gore.2023.101203.Peer-Reviewed Original ResearchLiposomal bupivacaineTransversus abdominis planeIncisional infiltrationOpioid requirementsPain scoresVertical laparotomyTAP blockGynecologic malignanciesBupivacaine hydrochlorideTransversus abdominis plane blockPilot studyOpen gynecologic surgeryTAP block groupTotal opioid useOpioid usePlane blockPostoperative periodSecondary outcomesPrimary outcomeGynecologic cancerInfiltration groupGynecologic surgeryClinical differencesGynecologic laparotomyBupivacaineTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.Peer-Reviewed Original ResearchConceptsHER2/neu expressionDS-8201aAntibody-drug conjugatesNeu expressionCS cell linesTrastuzumab deruxtecanOvarian carcinosarcomaTopoisomerase I inhibitor payloadCell linesAggressive gynecologic malignancyLimited therapeutic optionsEffective antibody-drug conjugatesCarcinosarcoma cell lineGynecologic malignanciesTherapeutic optionsIsotype controlSarcomatous elementsXenograft modelBystander killingFlow cytometryTumor cellsCarcinosarcomaAntitumor activityVivo studiesVivo activity
2021
EPV257/#152 Surgical site infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for gynecologic malignancy: a prospective randomized controlled trial
Moon A, andikyan V, Agarwal R, Stroever S, Misita D, Laibangyang A, Doo D, Chuang L. EPV257/#152 Surgical site infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for gynecologic malignancy: a prospective randomized controlled trial. International Journal Of Gynecological Cancer 2021, 31: a130-a130. DOI: 10.1136/ijgc-2021-igcs.328.Peer-Reviewed Original ResearchSurgical site infiltrationTransversus abdominis plane blockLiposomal bupivacaineTAP blockVertical laparotomyPain scoresSite infiltrationPlane blockGynecologic malignanciesVisual analog scale 0Significant differencesPain medication utilizationPostoperative analgesic techniqueMultivariable linear regressionOpioid consumptionTotal MMEAnalgesic effectAnalgesic techniquesMedication utilizationOpioid usePostoperative periodMedication useIncision lengthGynecologic cancerTotal morphine